மெழுகுவர்த்தி சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மெழுகுவர்த்தி சிகிச்சை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மெழுகுவர்த்தி சிகிச்சை Today - Breaking & Trending Today

Candel Therapeutics Announces Pricing of Initial Public Offering


Candel Therapeutics Announces Pricing of Initial Public Offering
NEEDHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the pricing of its initial public offering of 9,000,000 shares of common stock at a public offering price of $8.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on July 27, 2021 under the ticker symbol “CADL.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Candel, are expected to be $72 million. The offering is expected to close on July 29, 2021, subject to the satisfaction of customary closing conditions. In addition, Candel has granted the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock at the initial public offering price, less underwriting ....

New York , United States , Times Square , Heidi Chokeir , Equity Syndicate Department , Credit Suisse , Canale Communications , Credit Suisse Securities United States , Investment Bank , Exchange Commission , Prospectus Department , Equity Syndicate Prospectus Department , Candel Therapeutics Inc , Capital Markets Corp , Candel Therapeutics , Nasdaq Global Market , Suisse Securities , Stephens Drive , Markets Corp , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , முறை சதுரம் , பங்கு கூட்டமைப்பு துறை , கடன் ஸ்யூயி , கால்வாய் தகவல்தொடர்புகள் , கடன் ஸ்யூயி பத்திரங்கள் ஒன்றுபட்டது மாநிலங்களில் ,

Biliary Tract Cancers (BTC) Market Size Anticipated to Soar During the Forecast Period 2021-30 at a CAGR of 11.69% in the 7MM, Projects DelveInsight


Erdafitinib (Janssen Research and Development).
The anticipated launch of targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma shall push the growth of the BTC market size in the offing. 
Further, an increase in the BTC incidence, increment in healthcare spending, extensive R&D along better awareness of cancer is expected to give the BTC market size growth a much-needed momentum. 
Get in touch for a holistic view of the
The BTC market report also covers the market of Cholangiocarcinoma including (Intrahepatic and Extrahepatic), Gallbladder, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market s underlying potential, and plans strategically to tackle market risks. ....

United States , United Kingdom , Innovent Biologics , Roche Ipatasertib , Prnewswire Delveinsight , Chia Tai Tianqing , Derazantinib Basilea Pharmaceutica , Astellas Pharma Talazoparib , Regorafenib Bayer , Cholangiocarcinoma Intrahepatic , Shruti Thakur , Fite Biopharma , Basilea Pharmaceutica , Dohme Keytruda , Bristol Myers Squibb Opdivo , Dohme Lynparza , Entrectinib Hoffmann , Extrahepatic Cholangiocarcinoma , Novartis Lutathera , Janssen Research , Micurx Pharmaceuticals , Aeterna Zentaris , Signalrx Pharmaceuticals , Zai Lab Shanghai , Janssen Research Development Niraparib , Innovation Pharmaceuticals ,